Compare Adaptive Biotechnologies Corp (ADPT) vs Bank of New York Mellon Corp (BNY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Bank of New York Mellon Corp — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Bank of New York Mellon Corp trades at $149.66 (market cap $104.95B). The key difference: Bank of New York Mellon Corp is far larger — about 31.5× Adaptive Biotechnologies Corp's market cap, and Bank of New York Mellon Corp pays a 1.39% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | BNY | |
|---|---|---|
Market Cap | $3.33B | $104.95B |
Sector | Health | Financials |
52-Week High | $22.37 | $152.91 |
52-Week Low | $10.24 | $92.69 |
Enterprise Value | $3.19B | — |
Dividend Yield | — | 1.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
BNY Mellon stock trades at $152.91, up 4.29% on the day, near its consensus price target of $156. The stock shows strong momentum with three consecutive quarterly earnings beats and a bullish technical trend. Recent news highlights a planned 19% dividend increase to $0.63 per share and expansion into digital asset services, reflecting strategic growth initiatives. Revenue has grown steadily from $16.0B in 2022 to $19.8B in 2025, with net income margin improving to 29.21%.
The outlook remains positive with analyst consensus leaning toward 'Hold' but no 'Sell' ratings. Key opportunities include dividend growth and digital finance expansion, while risks involve high investing cash outflows and interest expense pressures. The stock's valuation at a P/E of 18.61 appears reasonable given profitability trends, but investors should monitor execution on capital investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Bank of New York Mellon Corp
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →
